Cargando…
A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment
OBJECTIVES: To understand the possible effect of a novel salt substitute with very low sodium in reducing blood pressure, salt intake and use of anti–hypertensive medications among patients on regular medications, to inform the future randomized trials. DESIGN: Single-arm pilot trial. SETTING: A com...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034699/ https://www.ncbi.nlm.nih.gov/pubmed/32080135 http://dx.doi.org/10.1097/MD.0000000000019263 |
_version_ | 1783499925199257600 |
---|---|
author | Mu, Lihong Li, Chenglong Liu, Ting Xie, Wuxiang Li, Ge Wang, Meixian Wang, Ruoxi Rao, Huakun He, Qin Wang, Wen Wu, Yangfeng |
author_facet | Mu, Lihong Li, Chenglong Liu, Ting Xie, Wuxiang Li, Ge Wang, Meixian Wang, Ruoxi Rao, Huakun He, Qin Wang, Wen Wu, Yangfeng |
author_sort | Mu, Lihong |
collection | PubMed |
description | OBJECTIVES: To understand the possible effect of a novel salt substitute with very low sodium in reducing blood pressure, salt intake and use of anti–hypertensive medications among patients on regular medications, to inform the future randomized trials. DESIGN: Single-arm pilot trial. SETTING: A community health service center in Chongqing, China. PARTICIPANTS: A total of 43 patients with hypertension taking anti-hypertensive medications regularly. INTERVENTION: Patients received the salt substitute with 18% sodium chloride for 8 weeks. MAIN OUTCOME MEASURES: Patients were followed up weekly for the use of antihypertensive medications and measurements of blood pressure. We collected 24-h urine before and after the trial to measure sodium and potassium intake. RESULTS: Among 39 patients who completed the 8 weeks’ intervention, 30.8% patients stopped or reduced anti-hypertensive medications during the trial. For patients that stopped or reduced medication, the mean SBP and DBP before intervention were 122.1 ± 9.6 and 68.9 ± 9.4 mm Hg and both did not increase after intervention (SBP change: 2.8 mm Hg (−5.1, 10.8), P = .48; DBP change: 1.8 mm Hg (−2.2, 5.7), P = .38). For the rest patients, the mean SBP and DBP before intervention were 141.6 ± 16.9 and 74.6 ± 6.6 mm Hg but reduced significantly after the intervention (SBP change: −16.0 mm Hg (−21.3, −10.6), P < .001; DBP change: −5.5 mm Hg (−8.1, −2.9), P < .001). The 24-h urine sodium decreased (P < .001) and potassium increased (P < .001) among all patients. No severe adverse events were reported. CONCLUSIONS: The novel salt substitute showed potential in reducing blood pressure and use of antihypertensive medications. Further randomized double–blind controlled trial is warranted to validate these findings. Clinical Trial Registration—URL:http://www.clinicaltrials.gov. Unique identifier: NCT03226327. |
format | Online Article Text |
id | pubmed-7034699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-70346992020-03-10 A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment Mu, Lihong Li, Chenglong Liu, Ting Xie, Wuxiang Li, Ge Wang, Meixian Wang, Ruoxi Rao, Huakun He, Qin Wang, Wen Wu, Yangfeng Medicine (Baltimore) 3400 OBJECTIVES: To understand the possible effect of a novel salt substitute with very low sodium in reducing blood pressure, salt intake and use of anti–hypertensive medications among patients on regular medications, to inform the future randomized trials. DESIGN: Single-arm pilot trial. SETTING: A community health service center in Chongqing, China. PARTICIPANTS: A total of 43 patients with hypertension taking anti-hypertensive medications regularly. INTERVENTION: Patients received the salt substitute with 18% sodium chloride for 8 weeks. MAIN OUTCOME MEASURES: Patients were followed up weekly for the use of antihypertensive medications and measurements of blood pressure. We collected 24-h urine before and after the trial to measure sodium and potassium intake. RESULTS: Among 39 patients who completed the 8 weeks’ intervention, 30.8% patients stopped or reduced anti-hypertensive medications during the trial. For patients that stopped or reduced medication, the mean SBP and DBP before intervention were 122.1 ± 9.6 and 68.9 ± 9.4 mm Hg and both did not increase after intervention (SBP change: 2.8 mm Hg (−5.1, 10.8), P = .48; DBP change: 1.8 mm Hg (−2.2, 5.7), P = .38). For the rest patients, the mean SBP and DBP before intervention were 141.6 ± 16.9 and 74.6 ± 6.6 mm Hg but reduced significantly after the intervention (SBP change: −16.0 mm Hg (−21.3, −10.6), P < .001; DBP change: −5.5 mm Hg (−8.1, −2.9), P < .001). The 24-h urine sodium decreased (P < .001) and potassium increased (P < .001) among all patients. No severe adverse events were reported. CONCLUSIONS: The novel salt substitute showed potential in reducing blood pressure and use of antihypertensive medications. Further randomized double–blind controlled trial is warranted to validate these findings. Clinical Trial Registration—URL:http://www.clinicaltrials.gov. Unique identifier: NCT03226327. Wolters Kluwer Health 2020-02-21 /pmc/articles/PMC7034699/ /pubmed/32080135 http://dx.doi.org/10.1097/MD.0000000000019263 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 3400 Mu, Lihong Li, Chenglong Liu, Ting Xie, Wuxiang Li, Ge Wang, Meixian Wang, Ruoxi Rao, Huakun He, Qin Wang, Wen Wu, Yangfeng A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
title | A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
title_full | A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
title_fullStr | A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
title_full_unstemmed | A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
title_short | A pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
title_sort | pilot study on efficacy and safety of a new salt substitute with very low sodium among hypertension patients on regular treatment |
topic | 3400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034699/ https://www.ncbi.nlm.nih.gov/pubmed/32080135 http://dx.doi.org/10.1097/MD.0000000000019263 |
work_keys_str_mv | AT mulihong apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT lichenglong apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT liuting apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT xiewuxiang apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT lige apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wangmeixian apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wangruoxi apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT raohuakun apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT heqin apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wangwen apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wuyangfeng apilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT mulihong pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT lichenglong pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT liuting pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT xiewuxiang pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT lige pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wangmeixian pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wangruoxi pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT raohuakun pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT heqin pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wangwen pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment AT wuyangfeng pilotstudyonefficacyandsafetyofanewsaltsubstitutewithverylowsodiumamonghypertensionpatientsonregulartreatment |